The iv infusion Bevacimab contains Bevacizumab and is made by Healthcare Pharmaceuticals Ltd. Bevacizumab is used in the treatment of several cancers.
There are 12 brands of Bevacizumab listed in Bangladesh. 8 of them have a lower unit price than Bevacimab. The lowest listed price is Bevastim 100 mg/4 ml IV Infusion at ৳ 13925.00 per unit.
What is Bevacimab 400 mg/16 ml IV Infusion?
Bevacimab comes as a iv infusion with 400 mg/16 ml of Bevacizumab, from Healthcare Pharmaceuticals Ltd. Bevacizumab works by binding to a protein called VEGF and blocking it from attaching to its receptors on the surface of endothelial cells. Bevacimab is given in a hospital or clinic setting under the supervision of a qualified cancer specialist, who chooses the treatment plan for each patient. Whether it suits you is a decision for your doctor.
Uses of Bevacimab
Bevacizumab is used in the treatment of several cancers. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines. It is often given together with chemotherapy as part of a wider treatment plan. Ask your doctor whether it is right for your condition.
How to use Bevacimab
It is not for self-administration at home. Bevacimab iv infusion is taken by mouth. The doctor decides the dose, the schedule and how long treatment continues, based on the type of cancer and other medicines being used.
Side effects of Bevacimab
Some people may experience side effects. Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat. Tell your doctor or nurse about any side effect, especially if it bothers you or does not settle.
Safety and precautions
The risk of certain blood vessel problems during treatment is increased in people with a history of arterial thromboembolism, diabetes, or older age; discuss your history with your doctor. The manufacturer's labelling does not list specific contraindications, but you should still tell your doctor about all your conditions and medicines. Bevacimab is given under specialist supervision, and the doctor decides whether it is suitable for you.
Frequently asked questions
What is Bevacimab used for?
Bevacizumab is used in the treatment of several cancers. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines.
How is Bevacimab used?
It is not for self-administration at home. Bevacimab iv infusion is taken by mouth.
What should I watch for while using Bevacimab?
Some people may experience side effects. Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat.
Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Pharmacology
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.
Dosage & Administration
Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.
Administer 5 mg/kg when used in combination with bolus-IFL.
Administer 10 mg/kg when used in combination with FOLFOX4.
Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.
Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.
Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.
Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/ kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).
Interaction
A drug interaction study was performed in which irinotecan was administered as part of the FOLFIRI regimen with or without Bevacizumab. The results demonstrated no significant effect of Bevacizumab on the pharmacokinetics of irinotecan or its active metabolite SN38.
In a randomized study in 99 patients with NSCLC, based on limited data, there did not appear to be a difference in the mean exposure of either carboplatin or paclitaxel when each was administered alone or in combination with Bevacizumab. However, 3 of the 8 patients receiving Bevacizumab plus paclitaxel/carboplatin had substantially lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel/carboplatin without Bevacizumab had a greater paclitaxel exposure at Day 63 than at Day 0.
Contraindications
There are no contraindications listed in the manufacturer’s labeling.
Side Effects
dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate or well controlled studies of bevacizumab in pregnant women. It is not known whether Avastin is secreted in human milk.
Precautions & Warnings
Arterial Thromboembolic Events. Among patients receiving Bevacizumab in combination with chemotherapy, the risk of developing ATE during therapy was increased in patients with a history of arterial thromboembolism, diabetes, or age greater than 65
Overdose Effects
The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine of 16 patients and with severe headache in three of 16 patients.
Storage Conditions
Bevacizumab vials are stable at 2 to 8° C. Bevacizumab vials should be protected from light. Do not freeze or shake. Diluted Bevacizumab solutions may be stored at 2 to 8° C for up to 8 hours. Store in the original carton until time of use. No incompatibilities between Bevacizumab and polyvinylchloride or polyolefin bags have been observed.
Alternative brands of Bevacizumab
Other brands with the same generic name, cheapest first.